

Fady I Malik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5075456/publications.pdf>

Version: 2024-02-01

17
papers

1,750
citations

687363

13
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1776
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure. <i>Science</i> , 2011, 331, 1439-1443. | 12.6 | 489 |
| 2 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116. | 27.0 | 381 |
| 3 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903. | 13.7 | 229 |
| 4 | Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. <i>Nature Medicine</i> , 2012, 18, 452-455. | 30.7 | 113 |
| 5 | Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 329-340. | 4.1 | 100 |
| 6 | Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108. | 2.8 | 73 |
| 7 | CK2127107 amplifies skeletal muscle response to nerve activation in humans. <i>Muscle and Nerve</i> , 2018, 57, 729-734. | 2.2 | 56 |
| 8 | Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. <i>Brain</i> , 2013, 136, 1718-1731. | 7.6 | 55 |
| 9 | Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model. <i>PLoS ONE</i> , 2014, 9, e96921. | 2.5 | 50 |
| 10 | Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171. | 7.1 | 47 |
| 11 | Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. <i>Journal of Medical Genetics</i> , 2013, 50, 383-392. | 3.2 | 46 |
| 12 | A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 287-299. | 1.7 | 42 |
| 13 | A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 584-594. | 1.7 | 29 |
| 14 | Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016. | 2.2 | 15 |
| 15 | Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 11 |
| 16 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 2212-2220. | 2.2 | 10 |
| 17 | Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtiv. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5008. | 4.1 | 4 |